STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.

MLA

Wang, Yan, et al. “STAT3 and STAT6 Polymorphisms Predict the Severity of Adverse Reactions in Chinese NSCLC Patients Receiving EGFR-TKIs Therapy.” Journal of Chemotherapy (Taylor & Francis Ltd), vol. 36, no. 1, Feb. 2024, pp. 61–71. EBSCOhost, https://doi.org/10.1080/1120009X.2023.2203610.

APA

Wang, Y., Qi, H., Wang, T., Zhang, W., Shi, X., Zhan, Q., Li, Q., & Zhong, M. (2024). STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy. Journal of Chemotherapy (Taylor & Francis Ltd), 36(1), 61–71. https://doi.org/10.1080/1120009X.2023.2203610

Chicago

Wang, Yan, Huijie Qi, Tianxiao Wang, Wenxin Zhang, Xiaojin Shi, Qiong Zhan, Qunyi Li, and Mingkang Zhong. 2024. “STAT3 and STAT6 Polymorphisms Predict the Severity of Adverse Reactions in Chinese NSCLC Patients Receiving EGFR-TKIs Therapy.” Journal of Chemotherapy (Taylor & Francis Ltd) 36 (1): 61–71. doi:10.1080/1120009X.2023.2203610.